AIMT Aimmune Therapeutics Inc.

16.94
-0.36  -2%
Previous Close 17.3
Open 17.42
Price To Book 4.71
Market Cap 1,105,347,841
Shares 65,250,758
Volume 535,475
Short Ratio
Av. Daily Volume 1,450,466
Stock charts supplied by TradingView

NewsSee all news

  1. Aimmune Therapeutics to Present at the RBC Capital Markets 2020 Global Healthcare Conference

    Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that its Chief Financial Officer, Eric

  2. Aimmune Therapeutics Announces First Quarter 2020 Financial Results and Provides Recent Operational Highlights

    Continues to be launch ready for PALFORZIATM EU and Swiss regulatory reviews for PALFORZIA remain on schedule Uninterrupted drug supply for all ongoing clinical trials $371.6 million cash, cash

  3. Aimmune Therapeutics to Host Conference Call and Webcast to Discuss First Quarter 2020 Financial Results and Recent Operational Highlights

    Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that it will host a conference call on

  4. Aimmune Therapeutics to Present at the 19th Annual Needham Virtual Healthcare Conference

  5. Aimmune Announces First U.S. Patients Are Being Treated with Newly-Approved PALFORZIA™, the First Treatment for Peanut Allergy

    Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that the first patients in the United

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial met primary endpoint - March 25, 2019.
AR101 ARTEMIS
Peanut Allergy
Phase 3 data released November 8, 2018 noted no serious adverse events
AR101 RAMSES
Peanut Allergy
FDA approval announced January 31, 2020.
PALFORZIA - AR101
Peanut Allergy
Phase 2 enrolment has closed due to cost cutting measures. Data due 1H 2021.
AR 201
Egg Allergy
Phase 2 trial initiation announced October 15, 2018.
AR101 with adjunctive dupilumab
Peanut Allergy
Phase 3 data due 1H 2021.
AR101 POSEIDON
Peanut Allergy

Latest News

  1. Aimmune Therapeutics to Present at the RBC Capital Markets 2020 Global Healthcare Conference

    Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that its Chief Financial Officer, Eric

  2. Aimmune Therapeutics Announces First Quarter 2020 Financial Results and Provides Recent Operational Highlights

    Continues to be launch ready for PALFORZIATM EU and Swiss regulatory reviews for PALFORZIA remain on schedule Uninterrupted drug supply for all ongoing clinical trials $371.6 million cash, cash

  3. Aimmune Therapeutics to Host Conference Call and Webcast to Discuss First Quarter 2020 Financial Results and Recent Operational Highlights

    Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that it will host a conference call on

  4. Aimmune Therapeutics to Present at the 19th Annual Needham Virtual Healthcare Conference

  5. Aimmune Announces First U.S. Patients Are Being Treated with Newly-Approved PALFORZIA™, the First Treatment for Peanut Allergy

    Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that the first patients in the United

  6. Aimmune Announces New PALFORZIA™ Data Suggesting Increased Desensitization, Improved Tolerability and Continued Immunomodulation After 18 and 24 Months of Treatment

    — Additional Data Highlight PALISADE Study Patient Baseline Characteristics and Associated Treatment Response — and Improvements in Self-Reported Quality of Life Following Long-Term Treatment with PALFORZIA — Survey

  7. Aimmune Therapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Recent Operational Highlights

    Launch underway for FDA-approved PALFORZIA™, the first treatment for peanut allergy In-licensing of AIMab7195 monoclonal antibody as potential adjunctive treatment with select CODIT™ programs Pro-forma cash and

  8. Aimmune Therapeutics to Present at Upcoming Investor Conferences

    Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that the Aimmune executive management team

  9. Aimmune to Present New Clinical Data at AAAAI Annual Meeting

    Nine Abstracts Will Highlight Data Including on the First FDA-Approved Treatment for Peanut Allergy and Oral Immunotherapy Practice Implementation in a Real-World Setting Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a

  10. Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2019 Financial Results and Recent Operational Highlights

    Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that it will host a conference call on

  11. Aimmune Therapeutics Announces Additional $200 Million Equity Investment by Nestlé Health Science

    ~Nestlé Health Science to Purchase Common and Convertible Preferred Aimmune Stock Bringing Total Investment in Aimmune to $473 Million to Date~ Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company

  12. Aimmune Licenses Exclusive Worldwide Rights to Xencor's XmAb®7195 for the Development of Next-Generation Food Allergy Treatments

    Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced it has obtained an exclusive worldwide license to develop and

  13. FDA Approves Aimmune's PALFORZIA™ as First Treatment for Peanut Allergy

    More than 1.6 Million Children and Teens in the U.S. are Allergic to Peanutsi,ii Company to Host Conference Call Today at 5:30 p.m. ET Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing

  14. Aimmune Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

    Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that its President and Chief Executive Officer, Jayson Dallas,

  15. Aimmune to Participate in Three Upcoming Investor Conferences

    Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that the Aimmune executive management team will participate in

  16. New Data Presented at ACAAI 2019 Show Importance of Clinical History in Identifying AR101-Eligibile Patients for PALISADE Study without a Food Challenge

    — Findings Suggest that a Strong Clinical History, in Combination with Evidence of Peanut Sensitization, is the Optimal Approach to Identify Highly Sensitive Peanut-Allergic Patients — Aimmune Therapeutics, Inc.

  17. Quality of Life Outcomes from Two New Surveys Highlight Emotional Impact of Peanut Allergy and Need for New Treatments

    —New Data at ACAAI Reinforce the Need for Treatments to Reduce the Fear of Accidental Exposure to Peanut and Improve Emotional Well-Being for Adult Patients and Caregivers— Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a

  18. New Real-World Data Unveiled at ACAAI Indicates Comparable Clinical Practice Logistics to Implement Oral Immunotherapy and Environmental Allergy Shots

    Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today revealed that the logistical needs for implementing oral immunotherapy

  19. AR101 Demonstrates Consistent Efficacy and Safety in New Analysis at ACAAI Comparing PALISADE and ARTEMIS Phase 3 Clinical Data

    —Despite Differing Study Designs, Patient Criteria and Geographies of the Two Landmark Clinical Trials, Results Were Consistent for AR101-Treated Patients Compared to Placebo— Aimmune Therapeutics, Inc. (NASDAQ:AIMT),

  20. Aimmune Therapeutics Announces Third Quarter 2019 Financial Results and Provides Operational Highlights

    --Webcast and conference call today at 4:30 p.m. ET-- Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced

  21. Aimmune to Participate in the Credit Suisse 28th Annual Healthcare Conference

    Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that members of the Aimmune executive management team will

  22. Aimmune to Present New Data on Safety and Efficacy of AR101, Clinical Practice Implementation of Oral Immunotherapy, Quality of Life and Other Related Studies at ACAAI 2019

    Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced it will present new data on the safety and efficacy of the

  23. Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Third Quarter 2019 Financial Results and Recent Operational Highlights

    Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it will host a conference call on Wednesday, November 6,

  24. Aimmune to Present at the Cantor Global Healthcare Conference

    Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that its President and Chief Executive Officer, Jayson Dallas, M.D., will

  25. FDA Allergenic Products Advisory Committee Votes to Support the Use of Aimmune's PALFORZIA™ (AR101) for Peanut Allergy

    Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that the Allergenic Products Advisory Committee (APAC)

  26. Aimmune Stock Trading Halted Today; FDA Allergenic Products Advisory Committee (APAC) Meeting to Discuss PALFORZIA™ (AR101) for Peanut Allergy

    Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that NASDAQ has halted trading of the company's common stock. The U.S.

  27. Biotech Brief: Latest Electrophysiology Devices Vastly Improving Diagnosis and Treatment of Cardiovascular Diseases

    PALM BEACH, Fla., Sept. 12, 2019 (GLOBE NEWSWIRE) -- According to a recent market research report published by Grand View Research, a consulting and advisory service firm that provides comprehensive, research-based

  28. Aimmune to Participate in Three Investor Conferences in September

    Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of the Aimmune executive management team will participate in